Healthcare · Medical Devices · United States
As of 2026-04-17 · Source: yfinance · Market: closed_weekend · Cache TTL 360 min
| 1 Day | +1.99% |
| 1 Month | +6.28% |
| 3 Months | -11.93% |
| YTD | -9.85% |
| 1 Year | +23.45% |
| 52-Week High | $89.77 |
| 52-Week Low | $59.95 |
| Market Cap | $34,066,624,512 |
| P/E (Trailing) | 16.41 |
| P/E (Forward) | 13.43 |
| EPS (TTM) | $4.55 |
| Dividend Yield | 19.00% |
| Beta | 1.30 |
| Revenue (TTM) | $20,625,000,448 |
| Profit Margin | 10.10% |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility